Back to homepage
Our expertise: Antimicrobials
Develop, test, and monitor your antimicrobials – from preclinical research to clinical programs and epidemiological surveillance.
With more than 15 years of academic research in antimicrobial resistance, Smaltis supports the development of your anti-infective products: antibiotics, antifungals, antimicrobial peptides, bacteriophages, strains with antimicrobial properties, vaccines/antibodies, hygiene and disinfection products, and any other antimicrobial compound.
Through our two business units – Research Microbiology and Precision Microbiology – we secure every stage, from in vitro screening to clinical validation.
Our offer
Comprehensive and precise solutions to support your anti-infective programs from research phases to epidemiosurveillance studies
| DEVELOPMENT STEPS |
1
Preclinical Research & Selection |
2
Resistance Risk Evaluation |
3
Clinical Studies & Epidemiological Surveillance |
| YOUR NEEDS |
• Candidate screening and selection |
• Anticipation of resistance emergence |
• Central Lab services |
| OUR SOLUTIONS |
→ Standard or customized MIC, MBC, time-kill assays, FIC Index (checkerboard assay) |
→ Serial passages |
→ Centralization, research & identification of isolates |
Our Promise: Expertise and know‑how to secure your developments
Bacteriology Platform Team
SANOFI
Cutting-edge expertise, rigor, and a collaborative spirit: with Smaltis, we have found a trusted partner for outsourcing the production of specific bacterial preparations. Reliable results, time savings, and peace of mind guaranteed.
Agustina LLANOS
Head of Biology
ANTABIO
We have collaborated with Smaltis on several occasions since 2014, notably as part of our ANT3273 project. This is an inhaled medicine targeting a key virulence factor of Pseudomonas aeruginosa involved in pathogenesis and would be an alternative or complement to existing antibiotic therapy for the treatment of P. aeruginosa infections in chronic respiratory diseases, such as bronchiectasis. Recently, Smaltis successfully completed a MLST sequencing project of a large number of strains with a very tight timeline to study the clonality of clinical isolates of P. aeruginosa from cystic fibrosis patients. The Smaltis team stands out for its expertise, proactive approach, and its communication and adaptability, which is why we continue to trust them.
Clara LEANDRO
Head of Infection
TECHNOPHAGE
The advancement of Technophage's therapeutic pipeline products has received crucial support from SMALTIS in the scope of genetic modification of bacterial strains. Throughout this collaborative effort, the SMALTIS scientific team has demonstrated remarkable commitment to resolving various technical challenges, successfully aligning with our objective of acquiring a set of strains for our internal utilization, all within the stipulated timeline.
Maxime GUALTIERI
CSO
NOSOPHARM
As part of our anti-infective molecule developments, we have repeatedly sought the expertise of the Smaltis team for cloning and construction of specific mutants. The services provided by Smaltis have notably contributed to our study describing and characterizing new mechanisms of resistance to Odilorhabdines in Klebsiella pneumoniae, which was published in 2021. We know that we can rely on their know-how and expert scientific advice for our future developments.
Olivier DHELLIN
Director of Pharmaceutical Development
NEOVACS
During our program to develop and industrialize the production of our Kinoïdes® vaccines, Smaltis has proven to be a partner of choice for optimizing one of our cytokine production systems. Its service consisted in optimizing the genetic heritage of the host bacterium by excising DNA from exogenous sequences. Very attentive and with a rare expertise in microbiology, the Smaltis team has always been benevolent and has never hesitated to guide us by providing sound advice. It is with pleasure that we will again call upon the services of Smaltis to help us in our next challenges.
Delphine GALLAND
Head of Preclinical Clinical Studies
VETOQUINOL
For the past 10 years, we have regularly turned to Smaltis for their services and expertise in microbiology, cellular biology, and molecular biology. The entrusted work focused on evaluating the efficacy and safety of various products related to infectious diseases. The smoothness of our interactions, the responsiveness of the entire team, and their adaptation to our regulatory requirements have allowed us to advance our research projects optimally. The trust we have placed in Smaltis over these 10 years has led us to include this provider among our preferred contacts.
Eric SAMARUT
Co-founder and Scientific Director
OSTA THERAPEUTICS
Smaltis is an important partner for us, with whom we have established a close and early relationship to support the development of our new anti-infective molecules. We sought their recognized expertise in the field of antimicrobials and antibiotic resistance to support our proof of concept of the efficacy of our compounds, using specific strains from their mutant collection. With the help of growth kinetics, determination of Minimal Inhibitory Concentrations, and precise construction of mutant strains, along with their insightful advice and regular constructive exchanges, we obtained solid and essential elements to secure our data and continue our project.